The Valley Desk

Clinical trial reportThe Lancet. Infectious diseasesPublished

Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
The Lancet. Infectious diseases
Published
PubMed ID
42863477
Added to directory
Source checked

Report a correction or request removal